Systemic Lupus Erythematosus Diagnosis and Monitoring

Clinical Diagnosis and Laboratory Findings

The American College of Rheumatology classification criteria for SLE should be used for diagnosis, which includes various combinations of clinical and laboratory findings, and the absence of skin findings does not exclude SLE 1, 2
Comprehensive autoantibody testing, including ANA, anti-dsDNA, anti-Ro/SSA, anti-La/SSB, anti-RNP, anti-Sm, and antiphospholipid antibodies, remains essential for diagnosis 1, 2
Complement levels (C3 and C4) should be measured to assess for systemic involvement, and baseline laboratory monitoring should include CBC, ESR, CRP, serum albumin, creatinine, and urinalysis with urine protein/creatinine ratio 1, 2

Patients with SLE lacking skin manifestations require the same systematic monitoring as those with cutaneous involvement, including follow-up every 6-12 months with CBC, ESR, CRP, serum albumin, creatinine, urinalysis, anti-dsDNA, C3, and C4 levels 1, 2
Regular assessment for development of new organ involvement, including renal, neuropsychiatric, hematologic, and cardiovascular manifestations, is critical, as some patients can develop serious organ-threatening disease, including lupus nephritis, neuropsychiatric lupus, and hematologic complications 1, 3
The Annals of the Rheumatic Diseases recommends assessment for renal involvement through serum creatinine, urine sediment analysis, proteinuria, and blood pressure, as these have predictive value for disease outcome 3